Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sinopharm Group Guizhou Blood Products Co., Ltd. is a specialized biopharmaceutical company focused on the research, development, and manufacturing of plasma-derived medicinal products (PDMPs). As a core subsidiary of Beijing Tiantan Biological Products under the China National Biotec Group (CNBG), the company operates as a key component of Sinopharm's integrated blood products platform. Its manufacturing facilities in Guizhou province are GMP-certified and utilize advanced plasma fractionation technologies to produce essential therapies, including human albumin, intravenous immunoglobulins, and coagulation factors. The company is dedicated to ensuring the safety and stability of the national blood product supply through rigorous quality control and extensive plasma station management. Its products are widely used in clinical settings for treating immune deficiencies, hemophilia, and critical care conditions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on 国药集团贵州血液制品有限公司.